AKT1 and cancer: Indeed, next-generation inhibitors are known to more completely inhibit mTORC1 and mTORC2 than rapamycin derivatives (as evidenced by 4EBP1 and AKT phosphorylation), and are more effective at inhibiting the growth of cancer cells in vitro and in mouse models (32, 33, 34).